SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases

To enhance the treatment efficacy of rectal cancer liver metastasis through a multidisciplinary approach of radiotherapy, immunotherapy, and chemotherapy, and to provide a new direction for the combination treatment strategy.

Trial Details

NCT ID

NCT06787183

Phase

PHASE2

Sponsor

Fujian Cancer Hospital

Status

RECRUITING

Cancer Type

Liver Cancer

Interventions

Short course radiotherapy
Capecitabine
Oxaliplatin
QL1706

Locations (sample)

Fuzhou, Fujian, China|26.06139,119.30611
Fuzhou, Fujian, China|26.06139,119.30611

Key Eligibility Criteria

Age 18-75 years, any gender.
Pathologically confirmed rectal cancer with liver metastases (stage M1).
Karnofsky Performance Status ≥70.
Adequate organ function, no contraindications to radiotherapy, or immunotherapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →